CL2015001442A1 - Metodo para tratar enfermedades pulmonares que comprende el uso de compuestos derivados del acido obeticolico. - Google Patents

Metodo para tratar enfermedades pulmonares que comprende el uso de compuestos derivados del acido obeticolico.

Info

Publication number
CL2015001442A1
CL2015001442A1 CL2015001442A CL2015001442A CL2015001442A1 CL 2015001442 A1 CL2015001442 A1 CL 2015001442A1 CL 2015001442 A CL2015001442 A CL 2015001442A CL 2015001442 A CL2015001442 A CL 2015001442A CL 2015001442 A1 CL2015001442 A1 CL 2015001442A1
Authority
CL
Chile
Prior art keywords
compounds derived
lung diseases
treating lung
obetolic
acid
Prior art date
Application number
CL2015001442A
Other languages
English (en)
Spanish (es)
Inventor
Mark Pruzanski
Luciano Adorini
Original Assignee
Intercept Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49753520&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2015001442(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intercept Pharmaceuticals Inc filed Critical Intercept Pharmaceuticals Inc
Publication of CL2015001442A1 publication Critical patent/CL2015001442A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2015001442A 2012-11-28 2015-05-27 Metodo para tratar enfermedades pulmonares que comprende el uso de compuestos derivados del acido obeticolico. CL2015001442A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261730749P 2012-11-28 2012-11-28

Publications (1)

Publication Number Publication Date
CL2015001442A1 true CL2015001442A1 (es) 2015-08-28

Family

ID=49753520

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015001442A CL2015001442A1 (es) 2012-11-28 2015-05-27 Metodo para tratar enfermedades pulmonares que comprende el uso de compuestos derivados del acido obeticolico.

Country Status (19)

Country Link
US (3) US20140148428A1 (enExample)
EP (1) EP2925328A1 (enExample)
JP (1) JP6270171B2 (enExample)
KR (1) KR102106186B1 (enExample)
CN (1) CN104853758A (enExample)
AU (1) AU2013352288B2 (enExample)
BR (1) BR112015012312A2 (enExample)
CA (1) CA2891348C (enExample)
CL (1) CL2015001442A1 (enExample)
HK (1) HK1211844A1 (enExample)
IL (1) IL239025B (enExample)
MX (1) MX2015006710A (enExample)
MY (1) MY170802A (enExample)
NZ (1) NZ708501A (enExample)
PH (1) PH12015501108B1 (enExample)
RU (1) RU2693382C2 (enExample)
SG (1) SG11201503697TA (enExample)
TW (1) TWI636786B (enExample)
WO (1) WO2014085474A1 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3985118A1 (en) 2013-11-22 2022-04-20 MiNA Therapeutics Limited C/ebp alpha short activating rna compositions and methods of use
WO2016045480A1 (zh) * 2014-09-28 2016-03-31 上海源力生物技术有限公司 一种奥贝胆酸的制备方法
EA034739B1 (ru) * 2014-11-19 2020-03-16 ЭнЗедПи ЮКей ЛИМИТЕД 6-альфа-алкил-3,7-дионовые стероиды в качестве промежуточных соединений для получения стероидных модуляторов fxr
MX381239B (es) * 2014-11-19 2025-03-12 Nzp Uk Ltd Esteroides de 6.alfa.-alquil-6,7-diona como intermedios para la producción de moduladores esteroideos del receptor x farnesoide (fxr).
JP6724004B2 (ja) * 2014-11-19 2020-07-15 エヌゼットピー ユーケー リミテッド ステロイドＦＸＲモジュレーター製造のための中間体としての５β−６−アルキル−７−ヒドロキシ−３−オンステロイド
EA033427B1 (ru) * 2014-11-19 2019-10-31 Nzp Uk Ltd 6-алкил-7-гидрокси-4-ен-3-оновые стероиды в качестве промежуточных соединений для получения стероидных модуляторов fxr
CN105348365A (zh) * 2014-12-03 2016-02-24 四川百利药业有限责任公司 一种胆酸衍生物及其制备方法、药物组合物和用途
CN105801653B (zh) * 2014-12-30 2018-04-17 苏州晶云药物科技有限公司 奥贝胆酸的晶型a及其制备方法
CZ2015504A3 (cs) * 2015-07-16 2017-01-25 Zentiva, K.S. Krystalické formy obeticholové kyseliny
CN105085597B (zh) * 2015-08-28 2017-03-29 成都百裕制药股份有限公司 一种无定型奥贝胆酸的制备方法
JP2018528230A (ja) * 2015-09-24 2018-09-27 インターセプト ファーマシューティカルズ， インコーポレイテッド 胆汁酸誘導体の調製のための方法および中間体
TW201718621A (zh) * 2015-10-07 2017-06-01 英特賽普醫藥品公司 法尼醇x受體調節劑
CN106589039B (zh) * 2015-10-15 2019-12-17 苏州朗科生物技术股份有限公司 一种奥贝胆酸的制备方法及相关化合物
CN106589038A (zh) * 2015-10-15 2017-04-26 重庆医药工业研究院有限责任公司 一种制备3α,7α-二羟基-6α-乙基-5β-胆烷酸的方法
CN106668027A (zh) * 2015-11-05 2017-05-17 中美华世通生物医药科技（武汉）有限公司 奥贝胆酸药物组合物及其制备方法
CN105399793A (zh) * 2015-12-24 2016-03-16 北京康立生医药技术开发有限公司 一种胆烷酸的制备方法
WO2017137931A1 (en) 2016-02-10 2017-08-17 Dr. Reddy’S Laboratories Limited Amine salt of obeticholic acid
WO2017170858A1 (ja) * 2016-03-31 2017-10-05 大日本住友製薬株式会社 溶出性に優れた経口製剤
CA3020698A1 (en) 2016-04-13 2017-10-19 Intercept Pharmaceuticals, Inc. Methods of treating or preventing hepatocellular carcinoma
GB201608777D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Compounds
GB201608776D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Methods and compounds
US10875887B2 (en) * 2016-06-01 2020-12-29 Dr. Reddy's Laboratories Limited. Process for preparation of obeticholic acid
CN106046095B (zh) * 2016-06-06 2017-02-22 南京理工大学 奥贝胆酸的合成方法
AU2017336803A1 (en) * 2016-09-30 2019-04-18 Intercept Pharmaceuticals, Inc. Crystalline forms of a bile acid derivative
CN108117579A (zh) * 2016-11-29 2018-06-05 昆明积大制药股份有限公司 奥贝胆酸及其中间体的制备方法
TW201832768A (zh) * 2017-03-07 2018-09-16 英特賽普醫藥品公司 治療癌症的方法
AU2018330494A1 (en) 2017-09-08 2020-03-26 Mina Therapeutics Limited HNF4a saRNA compositions and methods of use
KR20190030805A (ko) * 2017-09-14 2019-03-25 경상대학교산학협력단 폐고혈압 예방 또는 치료용 흡입제, 및 이의 투여방법
EP3705487B1 (en) * 2017-11-02 2022-10-26 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Method for preparing cholic acid compound
MX2021000925A (es) 2018-07-25 2021-03-31 Novartis Ag Inhibidores de inflamasoma nlrp3.
UY38687A (es) 2019-05-17 2023-05-15 Novartis Ag Inhibidores del inflamasoma nlrp3, composiciones, combinaciones de los mismos y métodos para su uso
WO2021044351A1 (en) 2019-09-06 2021-03-11 Novartis Ag Methods of treating liver disease using lta4h inhibitors
JP2022552655A (ja) 2019-10-07 2022-12-19 キャリーオペ，インク． Ｇｐｒ１１９アゴニスト
CN113318114B (zh) * 2020-02-28 2023-02-17 广州市赛普特医药科技股份有限公司 小分子化合物在治疗肺上皮细胞损伤和/或血管内皮细胞损伤介导的疾病中的用途
TW202140440A (zh) 2020-02-28 2021-11-01 美商克力歐普股份有限公司 Gpr40激動劑
AU2021275038A1 (en) 2020-05-19 2022-12-22 Kallyope, Inc. AMPK activators
CA3183575A1 (en) 2020-06-26 2021-12-30 Iyassu Sebhat Ampk activators
UY40374A (es) 2022-08-03 2024-02-15 Novartis Ag Inhibidores de inflamasoma nlrp3

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CY1308A (en) 1979-12-06 1985-12-06 Glaxo Group Ltd Device for dispensing medicaments
US4353656A (en) 1980-10-14 1982-10-12 Xerox Corporation Moving coil, multiple energy print hammer system including a closed loop servo
EP0069715B1 (en) 1981-07-08 1986-11-05 Aktiebolaget Draco Powder inhalator
GB2169265B (en) 1982-10-08 1987-08-12 Glaxo Group Ltd Pack for medicament
AT396333B (de) 1982-10-08 1993-08-25 Glaxo Group Ltd Vorrichtung zur verabreichung von medikamenten an patienten, einrichtung mit mehreren solchen vorrichtungen und traeger mit medikamentbehaeltern hiefuer
US4778054A (en) 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
DK163640C (da) 1985-07-30 1992-08-17 Glaxo Group Ltd Apparat til administrering af medikamenter
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
US5977095A (en) * 1993-03-09 1999-11-02 University Of Utah Research Foundation Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and respiratory distress syndrome
EP0870699A3 (en) 1995-03-10 1998-10-21 Minnesota Mining And Manufacturing Company Aerosol valves
GB9700226D0 (en) 1997-01-08 1997-02-26 Glaxo Group Ltd Inhalation device
US6632666B2 (en) 2000-01-14 2003-10-14 Biolife Solutions, Inc. Normothermic, hypothermic and cryopreservation maintenance and storage of cells, tissues and organs in gel-based media
EP1392714B1 (en) * 2001-03-12 2005-08-31 Intercept Pharmaceuticals, Inc. Steroids as agonists for fxr
WO2005032549A1 (en) * 2003-09-26 2005-04-14 Smithkline Beecham Corporation Compositions and methods for treatment of fibrosis
ES2533993T3 (es) 2004-03-12 2015-04-16 Intercept Pharmaceuticals, Inc. Tratamiento de fibrosis usando ligandos de FXR
ITMI20050912A1 (it) 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
SI2040713T1 (sl) * 2006-06-27 2014-11-28 Intercept Pharmaceuticals, Inc. Derivati žolčne kisline kot FXR ligandi za preprečevanje ali zdravljenje bolezni ali stanj, posredovanih s FXR
MX2008015923A (es) * 2006-06-29 2009-01-13 Hoffmann La Roche Derivados de bencimidazol, metodo para su produccion, su uso como agonistas fxr y preparaciones farmaceuticas que los contienen.
EP2324046B1 (en) * 2008-07-30 2014-09-03 Intercept Pharmaceuticals, Inc. Tgr5 modulators and methods of use thereof
JP5639073B2 (ja) * 2008-11-19 2014-12-10 インターセプト ファーマシューティカルズ， インコーポレイテッド Ｔｇｒ５モジュレーターおよびその使用方法
WO2010069604A1 (en) * 2008-12-19 2010-06-24 Royal College Of Surgeons In Ireland Treatment of diarrhoea
CN102712672B (zh) * 2009-08-25 2016-09-14 胆清医药有限公司 用于治疗胆疾病的多羟基化胆汁酸
US9416151B2 (en) * 2010-08-25 2016-08-16 Lurong ZHANG Use of glycyrrhetinic acid, glycyrrhizic acid and related compounds for prevention and/or treatment of pulmonary fibrosis
NZ734451A (en) * 2012-06-19 2018-12-21 Intercept Pharmaceuticals Inc Preparation, uses and solid forms of obeticholic acid

Also Published As

Publication number Publication date
US20140148428A1 (en) 2014-05-29
CA2891348C (en) 2020-04-28
TWI636786B (zh) 2018-10-01
RU2693382C2 (ru) 2019-07-02
AU2013352288A1 (en) 2015-06-04
NZ708501A (en) 2019-03-29
IL239025B (en) 2021-04-29
CN104853758A (zh) 2015-08-19
US20160213689A1 (en) 2016-07-28
EP2925328A1 (en) 2015-10-07
WO2014085474A1 (en) 2014-06-05
KR102106186B1 (ko) 2020-05-04
US20180064729A1 (en) 2018-03-08
IL239025A0 (en) 2015-07-30
SG11201503697TA (en) 2015-06-29
AU2013352288B2 (en) 2017-11-23
MY170802A (en) 2019-08-28
BR112015012312A2 (pt) 2017-07-11
CA2891348A1 (en) 2014-06-05
PH12015501108A1 (en) 2015-08-17
PH12015501108B1 (en) 2015-08-17
JP2016500111A (ja) 2016-01-07
KR20150089052A (ko) 2015-08-04
RU2015122027A (ru) 2017-01-10
TW201434469A (zh) 2014-09-16
HK1211844A1 (en) 2016-06-03
MX2015006710A (es) 2016-01-15
JP6270171B2 (ja) 2018-01-31

Similar Documents

Publication Publication Date Title
CL2015001442A1 (es) Metodo para tratar enfermedades pulmonares que comprende el uso de compuestos derivados del acido obeticolico.
LTC2785706I2 (lt) Pakeistieji 4-fenil-piridinai, skirti su nk-receptoriumi susijusių ligų gydymui
CL2015000177A1 (es) Composición para el tratamiento de la hiperlipidemia que comprende un derivado de oxintomodulina
PL2852391T3 (pl) Układy do leczenia infekcji płuc
BR112016022598A2 (pt) Formulação de rapamicina inalável para o tratamento de condições relacionadas com a idade
BR112014000033A2 (pt) compostos para o tratamento de dependência química
LT3159409T (lt) Antiprasminė nukleorūgštis, skirta panaudoti diušeno raumenų distrofijos gydymui
CO7061081A2 (es) Derivados macrocíclicos para el tratamiento de enfermedades
LT3010910T (lt) Pirimidindiono junginiai, skirti širdies ligoms
LT2916860T (lt) Diabeto gydymui skirta kompozicija, apimanti oksintomodulino analogą
LT2984166T (lt) Kompozicijos, skirtos mpsi gydymui
ZA201600317B (en) Bicyclic compounds useful for treating diseases caused by retroviruses
PT2872497T (pt) Derivados de cromanilo para o tratamento de doenças mitocondriais
EP2819978A4 (en) PROCESS FOR PRODUCTION OF 2,3,3,3-TETRAFLUOROPROPENE
BR112015002771A2 (pt) método para produzir tabaco com baixo teor de nitrosamina.
IT201600097392A1 (it) Metodo per la preparazione di acido 3-fluoroalchil-1-metilpirazol-4-carbossilico
CL2015000926A1 (es) Proceso para la elaboración de compuestos para el tratamiento del cancer derivados de azetidin-1-il-metanona y compuestos intermediarios.
BR112017011304A2 (pt) Processo para a preparação de ésteres de ácido láctico e ácido 2-hidroxi-3-butenoico ou alfa- hidroxi-análogos de metionina a partir de açúcares
CL2014001862A1 (es) Compuestos derivados de morofolinilo sustituido, útiles como inhibidores de mogat-2; composicion farmaceutica que los comprende; uso en el tratamiento de hipertrigliceridemia.
FR3009555B1 (fr) Procede de preparation de peroxydes organiques
IL238592B (en) Compounds for treatment of liver diseases
CL2017002304A1 (es) Métodos para tratar enfermedades
CO6990150A1 (es) Combinación de compuestos derivados del ácido gálico para el tratamiento del cáncer
HUE063095T2 (hu) Eljárások pirimidinilciklopentán vegyületek elõállítására
IL234796B (en) Compounds for the treatment of diseases related to ischemia-reperfusion